The Cytosolic DNA-Sensing cGAS-STING Pathway in Cancer - PubMed (original) (raw)

Review

The Cytosolic DNA-Sensing cGAS-STING Pathway in Cancer

John Kwon et al. Cancer Discov. 2020 Jan.

Abstract

The recognition of DNA as an immune-stimulatory molecule is an evolutionarily conserved mechanism to initiate rapid innate immune responses against microbial pathogens. The cGAS-STING pathway was discovered as an important DNA-sensing machinery in innate immunity and viral defense. Recent advances have now expanded the roles of cGAS-STING to cancer. Highly aggressive, unstable tumors have evolved to co-opt this program to drive tumorigenic behaviors. In this review, we discuss the link between the cGAS-STING DNA-sensing pathway and antitumor immunity as well as cancer progression, genomic instability, the tumor microenvironment, and pharmacologic strategies for cancer therapy. SIGNIFICANCE: The cGAS-STING pathway is an evolutionarily conserved defense mechanism against viral infections. Given its role in activating immune surveillance, it has been assumed that this pathway primarily functions as a tumor suppressor. Yet, mounting evidence now suggests that depending on the context, cGAS-STING signaling can also have tumor and metastasis-promoting functions, and its chronic activation can paradoxically induce an immune-suppressive tumor microenvironment.

©2019 American Association for Cancer Research.

PubMed Disclaimer

Conflict of interest statement

Disclosure of Potential Conflicts of Interest

SFB holds a patent related to some of the work described targeting CIN and the cGAS-STING pathway in advanced cancer. He owns equity in, receives compensation from, and serves as a consultant and the Scientific Advisory Board and Board of Directors of Volastra Pharmaceuticals Inc. He has also consulted for Sanofi. JK declares no conflicts of interest.

Figures

Figure 1.

Figure 1.. cGAS-STING signaling in immunity.

cGAS is an innate immune sensor that recognizes a diverse array of cytosolic dsDNA, which includes DNA with viral, apoptotic, exosomal, mitochondrial, micronuclei, and retroelement origins. cGAS oligomerizes with dsDNA in a 2:2 complex. The interaction of cGAS with DNA induces the formation of liquid droplets through phase transition, in which cGAS exerts its catalytic role to generate the second messenger 2’,3’-cGAMP. The presence of cGAMP stimulates STING at the ER, which undergoes higher-ordered tetramerization. STING translocates from the ER to Golgi compartments and is palmitoylated. STING serves as a signaling platform for TBK1 and IKK. TBK1 phosphorylates STING, which in turn recruits IRF3 for TBK1-mediated phosphorylation. Activated IRF3 dimerizes and translocates to the nucleus. IKK-mediated phosphorylation of the inhibitory IκB protein licenses nuclear entry of p50-RelA. Together with IRF3 in the nucleus, p50-RelA dimers stimulate the transcriptional expression of interferon and other immune-stimulatory genes. Artwork by Terry Helms, Graphics Department, MSKCC.

Figure 2.

Figure 2.. Independent functions cGAS and STING.

cGAS and STING possess alternative functions that diverge from the uniaxial and canonical cGAS-cGAMP-STING pathway, exerting effects that are independent from each other. Nuclear translocation of cytosolic cGAS has been shown to drive tumorigenesis through the blockade of HR repair in a STING-independent manner. Breakdown of the nuclear membrane in mitosis has been suggested to allow nuclear entry of cytosolic cGAS, which remains catalytically active and binds to centromeric satellites and LINE DNA repeats. On the other hand, STING can also be activated in a cGAS-independent manner. Etoposide-induced DNA damage recruits the DNA-damage response factors PARP-1 and ATM, which in turn activates STING to drive canonical NF-κB and IRF3-mediated interferon signaling. Artwork by Terry Helms, Graphics Department, MSKCC.

Figure 3.

Figure 3.. Tumor Suppressive Roles of cGAS-STING.

In early preneoplastic cells, the cGAS-STING pathway exerts its function as a tumor suppressor against oncogenic effects induced by DNA damage. Several sources of DNA damage, such as oxidative stress, radiation, low chromosome instability, hyper-activation of oncogene signaling, and chemotherapies, generates cytosolic DNA, which is sensed by cGAS within tumors. cGAS, in turn stimulates STING to upregulate the expression of type 1 IFN, ISG, and SASP genes. Through an unknown mechanism, STING-mediated autophagy may cooperate with IRF3 and canonical NF-κB signaling to inhibit or delay cancer progression. In addition, the cGAS-STING pathway allows crosstalk between tumors and neighboring immune cells to regulate antitumor immunity. Tumor-derived cGAMP and tumor DNA licenses antigen presenting cells, such as dendritic cells, to activate cGAS-STING signaling, triggering immune cells to mediate tumor clearance. Artwork by Terry Helms, Graphics Department, MSKCC.

Figure 4.

Figure 4.. Tumor Promoting Roles of cGAS-STING.

In metastatic tumor cells, the cGAS-STING pathway exerts its role in promoting tumorigenesis. Tumors with high chromosome instability generate micronuclei, which ruptures and releases DNA to the cytosol. STING serves as a signaling platform for a diverse array of tumorigenic programs. Chronic activation of STING signaling leads to suppression of type 1 IFN production and concurrent upregulation of noncanonical NF-κB signaling, pro-survival programs and metastasis. The release of immune-stimulating molecules, such as indoleamine 2,3-dioxygenase (IDO) and anti-inflammatory cytokines, from tumors allows the formation of an immunosuppressive microenvironment. STING may have additional roles in promoting immune evasion and metastasis through regulation of PD-L1 expression and induction of autophagy. Apart from cancer cell-autonomous roles of cGAS-STING, tumors can directly communicate with their external environment through the transfer of cGAMP to neighboring cells through gap junctions, which accelerates neoplastic progression. Artwork by Terry Helms, Graphics Department, MSKC.

Similar articles

Cited by

References

    1. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357(9255):539–45 doi 10.1016/S0140-6736(00)04046-0. - DOI - PubMed
    1. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986;315(26):1650–9 doi 10.1056/NEJM198612253152606. - DOI - PubMed
    1. Henson PM. Dampening inflammation. Nat Immunol 2005;6(12):1179–81 doi 10.1038/ni1205-1179. - DOI - PubMed
    1. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009;30(7):1073–81 doi 10.1093/carcin/bgp127. - DOI - PubMed
    1. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420(6917):860–7 doi 10.1038/nature01322. - DOI - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources